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Background: Cancer patients not admissible for adjuvant chemotherapy are generally at high risk of considerably
inferior prognosis. The aim of this retrospective study was to evaluate poorer survival without administration of oral
adjuvant chemotherapy of stage III colon cancer patients in clinical settings.
Methods: Between April 2007 and September 2011, 259 patients with stage III colon cancer who underwent
curative surgery were retrospectively assigned to the adjuvant chemotherapy group of 171 patients (66%) and the
surgery alone group of 88 patients. Oral fluorouracil (5-FU) derivatives used in adjuvant chemotherapy, such as oral
uracil and tegafur plus leucovorin (UFT/LV) or capecitabine, were the most commonly used.
Results: The 3-year relapse-free survival (RFS) rates were 74.9% for all cases, 58.3% for the surgery alone group, and
83.4% for the adjuvant chemotherapy group (P = 0.0001). The chemotherapy group was associated with a dramatic
improvement in survival for stage IIIB (surgery alone 57.7% versus adjuvant chemotherapy 83.9%; P = 0.0001) and
stage IIIC (surgery alone 18.2% versus adjuvant chemotherapy 57.3%; P = 0.006) patients. There was a significant
difference in the overall recurrence rate between groups (surgery alone 35.2% versus adjuvant chemotherapy
18.1%; P = 0.002). Multivariate analysis identified adjuvant therapy as an independent predictive factor of reduced
recurrence (hazard ratio (HR): 3.231; P = 0.004) and improved RFS (HR: 2.653; P = 0.001).
Conclusion: In clinical settings, adjuvant therapy was the only significant prognostic factor of survival. Since many
patients prefer not to receive chemotherapy, it is critical to inform stage III colon cancer patients that
chemotherapy raises their chances of survival by three-fold compared with curative surgery alone.
Keywords: Oral adjuvant chemotherapy, Colorectal cancer, Relapse-free survival, Overall survival, Capecitabine,
Tegafur plus leucovorinBackground
Adjuvant chemotherapy after curative resection for stage
III colon cancer patients has been widely recommended
as a standard treatment to prolong disease-free survival
(DFS) and overall survival (OS) since the early 1990s [1,2].
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) reported the results of a surgical adjuvant clin-
ical trial (protocol C-03) that indicated significant exten-
sion of DSF and OS in stage II and III colon cancer
patients who received fluorouracil (5-FU) plus leucovorin* Correspondence: tashiro@saitama-med.ac.jp
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unless otherwise stated.(LV) compared with patients who received semustine,
vincristine, and 5-FU (protocol C-04) [3-5]. Further-
more, the NSABP protocol C-06 demonstrated that oral
uracil and tegafur (UFT) plus LV (UFT/LV) were asso-
ciated with DSF and OS rates similar to those obtained
with a regimen of intravenous weekly bolus 5-FU plus LV
(5-year DFS 67.0% versus 68.2%, 5-year OS 78.5% versus
78.7%) [6-8]. 5-FU significantly improves DFS and OS rates
over surgery alone, with relative risk reductions of 30% and
26%, respectively [9].
The Xeloda® in Adjuvant Colon Cancer Therapy (X-
ACT) trial was undertaken to compare the efficacy and
tolerability of oral capecitabine with 5-FU/LV (intravenousLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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colon cancer [10,11]. The 3-year relapse-free survival
(RFS) rates were 65.5% with capecitabine and 61.9%
with 5-FU/LV, for an absolute difference of 3.6% (95%
CI, −0.9 to 8.1; P = 0.12). The 3-year OS rates were
81.3% with capecitabine and 77.6% with 5-FU/LV, giving an
absolute difference of 3.7% (95% CI, −0.1 to 7.5; P = 0.05)
between treatment groups. Since oral capecitabine offers
equivalent clinical benefits in terms of efficacy, safety, con-
venience, and treatment cost, it can replace intravenous 5-
FU/LV in the adjuvant treatment of stage III colon cancer.
Generally, patients not receiving adjuvant chemotherapy
have considerably inferior prognosis. The Japanese Society
for Cancer of the Colon and Rectum (JSCCR) reported re-
currence rates of 30.8% for stage III colon cancer [12].
The present retrospective study evaluated the progno-
sis of stage III colon cancer patients excluded from ad-
juvant chemotherapy because they were older patients,
had a high risk of severe comorbidities, or simply re-
fused to receive treatment.
The limitations of the study are that it has retrospective
clinical observations, a lack of patient randomization, and
a dependence on the information available in the patient
files. Which is more benefit or more harm associated with
various treatment strategies is decided depending on the
situation of each patients in clinical settings. Therefore,
the aim of this study was to demonstrate the poor progno-
sis without oral adjuvant chemotherapy for stage III colon
cancer patients in clinical settings.
Patients and methods
Patient selection criteria
Between April 2007 and September 2011, 259 patients
with stage III colon cancer who underwent curative
surgery were retrospectively assigned to the adjuvant
chemotherapy group (n = 171) or the surgery alone
group (n = 88). The database contained detailed infor-
mation on patient characteristics, operative findings,
histology, laboratory findings, and adjuvant therapies.
The follow-up survival data were collected retrospectively
through medical record analyses. The exclusion criteria
were as follows: rectal cancer; malignancy other than colon
cancer; and patients who did not receive adjuvant chemo-
therapy or did not have any information about the chemo-
therapy. Cancer was staged using the American Joint
Committee on Cancer (AJCC) 7th edition TNM classi-
fication: colon and rectum [13].
Chemotherapy adjuvant regimens
All patients started receiving adjuvant ≥8 weeks after
curative surgery. They were required to have an Eastern
Cooperative Oncology Group (ECOG) performance status
of 0 to 2, to have signed informed consent, and be aged
between 20 and 80 years old. The JSCCR recommendsfour adjuvant therapy regimens for stage III colorectal
cancer: intravenous 5-FU/LV, UFT/LV, capecitabine, or
FOLFOX (5-FU/LV plus oxaliplatin). In Japan, given the
expected benefits and possible risks of toxicity, a consen-
sus has not been reached as to whether adjuvant regimens
containing oxaliplatin should be given to stage III patients.
Several oral 5-FU derivatives are available, such as oral
UFT/LV or capecitabine, and they are preferred for their
convenience. Consequently, these were the most com-
monly used regimens in this study [14].
The UFT regimen is a preparation of tegafur-uracil in
a molar ratio of 1:4. Tegafur is the 5-FU prodrug con-
verted to 5-FU in the liver. LV is used to modulate 5-FU
biochemically, and has been widely adopted for the
treatment of advanced colorectal cancer [8,15]. The 5-
week cycles of chemotherapy consisted of 4 weeks of
oral UFT/LV, followed by 1 week of rest, and were re-
peated for ≥6 months. The UFT was administered at a
dose of 300 mg/m2/day, and LV was administered at a
dose of 75 mg/day. The daily doses of UFT/LV were di-
vided into three doses administered every 8 h with
water. Patients were instructed to avoid food from 1 h
before to 1 h after each dose. Capecitabine is an oral
fluoropyrimidine that generates 5-FU preferentially in
tumor tissue through a three-step enzymatic cascade
[16]. The adjuvant was administered at a dose of
1.250 mg/m2 twice a day for 14 days, followed by 7 days
of rest. Standard care included a total of eight cycles.
The amount of drug received was based on reported pill
counts and patient declarations at the end of each cycle.
Follow-up protocol
The patients were scheduled for follow-up visits every
3 months during the first 3 years, every 6 months during
the next 2 years, and annually thereafter. Each visit in-
cluded a physical examination and computed tomog-
raphy (CT) scans of the chest, abdomen, and pelvis.
Colonoscopies were performed during the first, third,
and fifth year of follow-up. The median follow-up period
was 41 months (range: 3 to 73 months).
Data analysis
Statistical analysis was performed using SPSS version
21.0 software (SPSS Inc., Chicago, IL, USA). The chi-
squared test or Fisher’s exact probability test were used
to compare recurrence rates. Logistic regression analysis
was conducted on the parameters found to be signifi-
cantly associated with recurrence by chi-squared tests or
Fisher’s exact probability test (P <0.05) to identify the in-
dependent factors of recurrence. Survival rates were calcu-
lated by the Kaplan–Meier method and compared by the
log-rank test. Stepwise forward Cox regression model was
conducted for parameters found to be significantly associ-
ated with survival by the log-rank test (P <0.05) in order
Table 1 Comparison of patient characteristics stratified
according to receipt of adjuvant chemotherapy and









Age (years, mean) 75.4 63.4 <0.0001
Comorbidity 60 (68%) 82 (47%) 0.002
ASA (grade ≥3) 27 (30%) 2 (1%) <0.0001
Location
Right side of colon 36 62 0.47
Left side of colon 52 109
Colon 77 136 0.11
Rectosigmoid 11 35
Serum CEA
≥5 36 (41%) 73 (43%) 0.78









26 (30%) 46 (27%) 0.65
Tumor depth
T1/T2/T3/T4 13/5/52/18 9/15/113/34 0.06
Lymph node
metastasis
N1 (1 to 3) 65 131 0.33
N2 (4≤) 23 40
Lymph node
number (≥12)
81 (92%) 161 (94%) 0.52
TNM stage













ASA, American Society of Anesthesiologists physical status classification
system; CEA, carcinoembryonic antigen; TNM, tumor, node, metastasis.
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P <0.05 were considered significant in all analyses. This
analysis was conducted using the intention-to-treat theory.
Results
Patient characteristics
The two groups were similar with respect to gender,
tumor location, depth of invasion, tumor differen-
tiation and lymphovascular invasion, and TNM sub-
classification (IIIA/IIIB/IIIC) (Table 1). However, mean
age was significantly higher in the surgery alone group
(63.4 versus 75.4 years; P <0.0001). The causes for ad-
juvant chemotherapy rejection were older patients
(>80 years), high risk of severe comorbidities or post-
operative complication, and self-judgment of refusal.
Prevalence of each adjuvant regimen
The UFT/LV regimen was performed in 104 patients
(61%), capecitabine in 59 patients (34%), and other types
in eight patients (5%; S1 and single-agent of UFT).
The overall compliance was 77%, as 40 patients dis-
continued the therapy without evidence of a protocol
event. The most common symptoms of drug toxicity
were severe nausea and diarrhea (3.5%); the risks of
severe hepatitis, neutropenia, and hand foot syn-
drome (5%) only with capecitabine. The completion
rate of adjuvant chemotherapy was significantly less
in patients with UFT/LV (72%) than with capecitabine
(83%; P <0.0001).
Survival analysis
The Kaplan–Meier estimates of 3-year OS and 3-year
RFS survival are presented in Figure 1 and Figure 2, re-
spectively. When the two groups were compared, the ad-
juvant chemotherapy was associated with a significant
improvement in 3-year OS (surgery alone: 81.7% versus
adjuvant chemotherapy: 93.5%; P <0.001) and RFS (sur-
gery alone: 58.3% versus adjuvant chemotherapy: 83.4%;
P <0.001). Furthermore, chemotherapy did not affect the
3-year OS of stage IIIA and IIIC patients, and the 3-year
RFS of stage IIIA patients.
Univariate and multivariate analyses were conducted
for each clinicopathological factor (Table 2). Based on
univariate analysis, advanced age was associated with
poorer survival, whereas adjuvant chemotherapy was as-
sociated with improved survival. Multivariate analysis
was performed to identify independent predictors of sur-
vival. Chemotherapy was the only significant prognostic
factor of improved survival (hazard ratio (HR): 0.379;
95% confidence interval (CI), 0.214 to 0.670; P = 0.001),
aside from oncological factors (depth of tumor invasion
and TNM stage).
Cancer recurrence occurred in 62 patients (recurrence
rate (rec rate), 23.9%) during the follow-up period. Therisk of recurrence during the first 3 years was two-fold
higher for surgery alone (rec rate, 35%) than with adju-




















Figure 1 Kaplan–Meier estimates of 3-year relapse-free survival (RFS) of all cases, and patients with stage IIIA, IIIB, and IIIC colon
cancer. Survival analysis compares the surgery alone group and chemotherapy group.
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was 10.5 months. In the surgery only group, the re-
currence sites included the liver (12 patients, 38%), lung
(five patients, 16%), dissemination (two patients, 6%),






Figure 2 Kaplan–Meier estimates of 3-year overall survival (OS) of all
Survival analysis compares the surgery alone group and chemotherapy gro(four patients, 13%). In the adjuvant chemotherapy group,
the recurrence sites were the liver (seven patients, 22.5%),
lung (seven patients, 22.5%), dissemination (seven pa-
tients, 22.5%), local sites (one patient, 3%), and lymph






cases, and patients with stage IIIA, IIIB, and IIIC colon cancer.
up.
Table 2 Univariate and multivariate regression analysis for relapse-free survival (RFS) of stage III colon cancer
Variable Comparison Univariate Multivariate
P value HR 95% CI P value
Gender Female versus male 0.24
Age 0.001 1.01 0.986 to 1.043 0.324
Comorbidity No versus yes 0.745
ASA (grade ≥3) No versus yes 0.008 1.000 0.505 to 1.98 0.999
Location Right versus left side of colon 0.306
Colon versus rectosigmoid 0.406
Serum CEA <5 versus ≥5 0.074 0.84 0.519 to 1.366 0.49
Operation Laparoscopic versus open surgery 0.082 1.01 0.597 to 1.700 0.98
Tumor depth T1, 2 versus T3, 4 0.002 0.26 0.089 to 0.733 0.01
Lymph node metastasis N1 (1 to 3) versus N2 (4<) 0.004 0.71 0.387 to 1.301 0.27
TNM stage IIIA, B versus IIIC <0.0001 0.4 0.204 to 0.797 0.01
Adjuvant chemotherapy No versus yes <0.0001 2.65 1.48 to 4.756 0.001
ASA, American Society of Anesthesiologists physical status classification system; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio;
TNM, tumor, node, metastasis.
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dent predictive factors of recurrence (Table 3). Chemothe-
rapy was the only significant predictive factor of recurrence
(HR, 3.076; 95% CI, 1.422 to 6.653; P = 0.004) apart
from oncological factors (depth of tumor invasion and
TNM stage).
Discussion
Recently, practice-based research (studies based on med-
ical care) which got rid of the distance of a clinician and
the researcher tends to be regarded as important [17]. It
is a valuable study method that provides information
from daily clinical situations. The present study provides
the survival outcome of stage III colon cancer patients.
We report that patients treated only by curative surgery
for various reasons had considerably inferior prognosisTable 3 Multivariate regression analysis for cancer recurrence
Variable Comparison
Age
Comorbidity No versus yes
ASA (grade ≥3) No versus yes
Location Right versus left side of colon
Serum CEA <5 versus ≥5
Operation Laparoscopic versus open surgery
Morbidity No versus yes
Tumor depth T1, 2 versus T3, 4
Lymph node metastasis N1 (1 to 3) versus N2 (4<)
TNM stage IIIA, B versus IIIC
Adjuvant chemotherapy No versus yes
CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio.than those receiving both surgery and chemotherapy.
Oncologists are aware of this, but tend to disregard fac-
tors affecting the efficacy of adjuvant chemotherapy, such
as age, comorbidity, and postoperative patient conditions.
Cohort studies including these parameters would provide
a more comprehensive analysis of cancer treatment out-
come. For patients intolerant to anticancer drugs, can-
cer recurrence and prognosis due to aggravation of
serious comorbidity are important factors influencing
survival. The survival rates we present for surgery alone
are more realistic because they account for the patients
who refused chemotherapy for economic, social, or philo-
sophical reasons.
The 3-year RFS rate of the surgery alone group was
significantly lower than for the chemotherapy group. In
addition, chemotherapy was associated with a two-foldof stage III colon cancer
Multivariate
HR 95% CI P value
1 0.968 to 1.036 0.941
0.96 0.490 to 1.864 0.895
1.34 0.452 to 3.994 0.595
1.08 0.561 to 2.089 0.81
0.61 0.316 to 1.167 0.135
1.08 0.503 to 2.301 0.85
0.64 0.189 to 2.154 0.47
0.17 0.037 to 0.801 0.03
0.56 0.244 to 1.268 0.16
0.29 0.106 to 0.785 0.02
3.23 1.458 to 7.159 0.004
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stage III colorectal cancer patients, with 18% and 35%, re-
spectively. Both stage IIIB and IIIC patients benefited
from chemotherapy with a dramatic improvement in sur-
vival rate over surgery alone. Multivariate analysis only
identified chemotherapy as an independent predictive fac-
tor for improvements in prognosis and reduction in can-
cer recurrence. Therefore, patients unable or unwilling to
receive chemotherapy have a poor oncological prognosis.
It is critical to provide this information to the patients un-
able to receive adjuvant chemotherapy for stage IIIB and
IIIC. When recurrence occurs in stage IIIB and IIIC colon
cancer patients, the oncologic surgeon who makes the
decision of surgery alone treatment will provide the best
supportive care.
The present study emphasizes the needless of chemo-
therapy in cases of stage IIIA colon cancer. Whereas both
groups had an excellent outcome, chemotherapy after sur-
gery raised the 3-year RFS from 87.4% to 100%. While the
sample sizes were too small to reach statistical signifi-
cance, it is likely that chemotherapy could be omitted for
certain types of stage IIIA colon cancer with low risk of
recurrence, such as node positive T1/T2 patients. Adju-
vant administration must be decided based on the status
of each patient with stage IIIA colon cancer. While the
benefits of 100% 3-year RFS is important for patients, it
must be weighed against the adverse effects.
We must determine how to improve the treatment of pa-
tients with poor performance status, severe comorbidities,
and older patients who are not normally eligible for chemo-
therapy [18]. The older age patient group is commonly
overlooked in clinical trials and, as a result, is often under-
treated despite the proven efficacy of adjuvant therapy
[19,20]. The X-ACT trial added to the growing volume
of evidence suggesting that age alone should not be a
barrier to the use of adjuvant chemotherapy in colon can-
cer [21,22]. On the other hand, performance status should
be the governing factor. In addition, it is important to re-
member that renal impairment is more common in older
patients, and is associated with an increased risk of tox-
icity with UFT/LV or capecitabine. Renal function should
therefore be assessed before the onset of chemotherapy.
The most appropriate type of chemotherapy requires a
risk-benefit assessment of each adjuvant regimen available
based on age, disease stage, performance status, comor-
bidities, and patient preference. For cancer patients hospi-
talized for severe comorbidities, an immunity activation
agent (that is, polysaccharide-K) may be added to single-
agent UFT, but the impact on recurrence has not been de-
termined [23].
Conclusion
Although other reports have documented treatment out-
comes in stage III colon cancer, the present study analyzeda rare subset of colon cancer patients (stage IIIA, IIIB, and
IIIC) treated only with oral adjuvant chemotherapy at a
single institution. Receiving adjuvant chemotherapy was
the only prognostic factor for an improved treatment out-
come in a clinical setting. Patients that are uncertain about
the benefits of adjuvant chemotherapy should be informed
of the poor survival rates for stage IIIB and IIIC colon
cancer, as well as the excellent survival rates for stage IIIA
colon cancer without adjuvant chemotherapy. Unfortu-
nately, stage IIIB and IIIC colon cancer patients who can-
not undergo adjuvant chemotherapy because of severe
comorbidities, an advanced age, or by choice, need to be
informed of the inferior prognosis without treatment.
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